Baoxia J. Dong

No. 100 Haining Road
Shanghai, 200080, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Short-course blinatumomab as a bridge-to-transplantation improves the survival of Ph-negative MRD-positive B-ALL.

Short-course blinatumomab as a bridge-to-transplantation improves the survival of Ph-negative MRD-positive B-ALL.

Journal: Cell transplantation

Published: July 07, 2026

Venetoclax-enhanced reduced-intensity conditioning in older patients aged ≥55 years with high-risk myeloid malignancies undergoing allogeneic peripheral blood stem cell transplantation: A phase II study.

Venetoclax-enhanced reduced-intensity conditioning in older patients aged ≥55 years with high-risk myeloid malignancies undergoing allogeneic peripheral blood stem cell transplantation: A phase II study.

Journal: British journal of haematology

Published: January 29, 2026

A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy.

A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy.

Journal: Blood

Published: November 25, 2025

Microbial DNA analysis of paired blood-bronchoalveolar lavage fluid in post-HSCT patients with pneumonia implying application conditions of blood as a surrogate in pathogen detection.

Microbial DNA analysis of paired blood-bronchoalveolar lavage fluid in post-HSCT patients with pneumonia implying application conditions of blood as a surrogate in pathogen detection.

Journal: Respiratory research

Published: November 09, 2025

Age- and comorbidity-adjusted busulfan, fludarabine, cytarabine, and low-dose TBI-based conditioning regimen is effective for myelodysplastic syndromes with excess blasts undergoing allogeneic peripheral blood stem cell transplantation.

Age- and comorbidity-adjusted busulfan, fludarabine, cytarabine, and low-dose TBI-based conditioning regimen is effective for myelodysplastic syndromes with excess blasts undergoing allogeneic peripheral blood stem cell transplantation.

Journal: Cell transplantation

Published: October 18, 2025

Parous female donor confers superior relapse protection in Haplo-PBSCT: A multicenter study of ATG/PTCy combination-based GVHD prophylaxis in AML/MDS.

Parous female donor confers superior relapse protection in Haplo-PBSCT: A multicenter study of ATG/PTCy combination-based GVHD prophylaxis in AML/MDS.

Journal: Bone marrow transplantation

Published: October 15, 2025

Droplet Digital PCR Outperforms Conventional Methods for Early Relapse Prediction in Acute Myeloid Leukemia/Myelodysplastic Syndrome Patients Post-Transplantation.

Droplet Digital PCR Outperforms Conventional Methods for Early Relapse Prediction in Acute Myeloid Leukemia/Myelodysplastic Syndrome Patients Post-Transplantation.

Journal: Transplantation and cellular therapy

Published: August 15, 2025

VLA-4 agonist promotes engraftment and immune reconstitution of allogeneic hematopoietic stem cells.

VLA-4 agonist promotes engraftment and immune reconstitution of allogeneic hematopoietic stem cells.

Journal: Blood advances

Published: June 12, 2025

T cell receptor-engineered T cells targeting the TP53R248Q neoantigen elicit antitumor effects in human cancer models.

T cell receptor-engineered T cells targeting the TP53R248Q neoantigen elicit antitumor effects in human cancer models.

Journal: The Journal of clinical investigation

Published: June 10, 2025

Lymphocyte subset reconstitution and clinical outcomes following haploidentical hematopoietic stem cell transplantation.

Lymphocyte subset reconstitution and clinical outcomes following haploidentical hematopoietic stem cell transplantation.

Journal: British journal of cancer

Published: May 27, 2025

IPSS-M outperforms IPSS-R in prognostic stratification and guides effective interventions for very High-Risk myelodysplastic syndrome patients undergoing allogeneic hematopoietic stem cell transplantation.

IPSS-M outperforms IPSS-R in prognostic stratification and guides effective interventions for very High-Risk myelodysplastic syndrome patients undergoing allogeneic hematopoietic stem cell transplantation.

Journal: Discover oncology

Published: January 31, 2025

Parous female donor is not inferior to the young male donor under the low-dose ATG/PTCy combination-based regimen for GVHD prophylaxis in haploidentical peripheral blood stem cell transplantation.

Parous female donor is not inferior to the young male donor under the low-dose ATG/PTCy combination-based regimen for GVHD prophylaxis in haploidentical peripheral blood stem cell transplantation.

Journal: Leukemia research

Published: January 27, 2025

Showing 1-12 of 35

Last Updated: 09/26/2026